Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)

被引：21

作者：

Mildner, Finn ^{[1
,3
]}

Sopper, Sieghart ^{[1
,3
]}

Amann, Arno ^{[1
,3
]}

Pircher, Andreas ^{[1
]}

Pall, Georg ^{[1
]}

Koeck, Stefan ^{[1
,3
]}

Naismith, Erin ^{[1
]}

Wolf, Dominik ^{[1
,2
,3
]}

Gamerith, Gabriele ^{[1
,3
]}

机构：

[1] Med Univ Innsbruck, Internal Med Hematol & Oncol 5, Anichstr 35, A-6020 Innsbruck, Austria

[2] Univ Hosp Bonn UKB, Internal Med Oncol Hematol Immunoncol Rheumatol 3, Venusberg Campus 1, D-53127 Bonn, Germany

[3] Tiroler Krebsforsch Inst TKFI, Innrain 66, A-6020 Innsbruck, Austria

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Immunotherapy; Liquid biopsy; NSCLC; Biomarker; Longitudinal monitoring; Tumor-immune microenvironment; CIRCULATING TUMOR-CELLS; PERIPHERAL-BLOOD; PD-L1; EXPRESSION; LIQUID BIOPSY; IMMUNE-CHECKPOINTS; METASTATIC NSCLC; OPEN-LABEL; T-CELLS; MUTATION; DNA;

D O I：

10.1016/j.critrevonc.2020.102948

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the highly dynamic field of advanced malignancies, biomarkers from liquid samples are urgently needed to improve treatment tailoring. However, the heterogenic data lack direct comparison of assays, vectors and re-levant validations are rarely found. Therefore, we classified the available studies based on three categories: Measured vectors, applied technique and detected biomarker. High blood tumor mutational burden and low baseline levels of soluble programmed cell death 1 ligand 1 (PD-L1) appear to predict treatment responses to immunotherapy. A high PD-1(+) CD4(+) T-cell count was asso-ciated with poor overall survival, PD-1(+)CD8(+) T-cells connect to a favorable outcome. Circulating tumor cells expressing PD-L1 were mainly associated with poor overall survival and treatment failure. Conclusion: Measurement of immunological factors as liquid biomarkers is feasible and has shown promising results. The use of coherent nomenclatures, cross-platform assay comparisons and validations through appropriate powered clinical trials are urgently required to push this auspicious field.

引用

页数：12

共 104 条

[1] The clinical significance of soluble PD-1 and PD-L1 in lung cancer [J].

Abu Hejleh, Taher ;

Furqan, Muhammad ;

Ballas, Zuhair ;

Clamon, Gerald .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 :148-152

[2] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Forde, Patrick M. ;

White, James R. ;

Niknafs, Noushin ;

Hruban, Carolyn ;

Naidoo, Jarushka ;

Marrone, Kristen ;

Sivakumar, I. K. Ashok ;

Bruhm, Daniel C. ;

Rosner, Samuel ;

Phallen, Jillian ;

Leal, Alessandro ;

Adleff, Vilmos ;

Smith, Kellie N. ;

Cottrell, Tricia R. ;

Rhymee, Lamia ;

Palsgrove, Doreen N. ;

Hann, Christine L. ;

Levy, Benjamin ;

Feliciano, Josephine ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Isbell, James M. ;

Sauter, Jennifer L. ;

Taube, Janis ;

Scharpf, Robert B. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Chaft, Jamie E. ;

Hellmann, Matthew D. ;

Brahmer, Julie R. ;

Velculescu, Victor E. .

CANCER RESEARCH, 2019, 79 (06) :1214-1225

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients [J].

Arrieta, Oscar ;

Montes-Servin, Edgar ;

Hernandez-Martinez, Juan-Manuel ;

Cardona, Andres F. ;

Casas-Ruiz, Eibar ;

Crispin, Jose C. ;

Motola, Daniel ;

Flores-Estrada, Diana ;

Barrera, Lourdes .

ONCOTARGET, 2017, 8 (60) :101994-102005

[5] Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer [J].

Bennett, Catherine W. ;

Berchem, Guy ;

Kim, Yeoun Jin ;

El-Khoury, Victoria .

ONCOTARGET, 2016, 7 (43) :71013-71035

[6] Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival [J].

Boffa, Daniel J. ;

Graf, Ryon P. ;

Salazar, Michelle C. ;

Hoag, Jessica ;

Lu, David ;

Krupa, Rachel ;

Louw, Jessica ;

Dugan, Lyndsey ;

Wang, Yipeng ;

Landers, Mark ;

Suraneni, Mahipal ;

Greene, Stephanie B. ;

Magana, Marisa ;

Makani, Samir ;

Bazhenova, Lyudmila ;

Dittamore, Ryan V. ;

Nieva, Jorge .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (07) :1139-1145

[7] Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis [J].

Bonomi, Marcelo ;

Ahmed, Tamjeed ;

Addo, Safoa ;

Kooshki, Mitra ;

Palmieri, Dario ;

Levine, Beverly J. ;

Ruiz, Jimmy ;

Grant, Stefan ;

Petty, William J. ;

Triozzi, Pierre L. .

ONCOLOGY LETTERS, 2019, 17 (01) :1349-1356

[8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[9] Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice [J].

Boutsikou, Efimia ;

Domvri, Kalliopi ;

Hardavella, Georgia ;

Tsiouda, Dora ;

Zarogoulidis, Konstantinos ;

Kontakiotis, Theodoros .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

[10] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review [J].

Brody, Robert ;

Zhang, Yiduo ;

Ballas, Marc ;

Siddiqui, Mohd Kashif ;

Gupta, Palvi ;

Barker, Craig ;

Midha, Anita ;

Walker, Jill .

LUNG CANCER, 2017, 112 :200-215

← 1 2 3 4 5 6 7 8 9 10 →